| scholarly article | Q13442814 |
| P50 | author | Lydie Trautmann | Q64711548 |
| P2860 | cites work | Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells | Q45874051 |
| A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection | Q46280014 | ||
| Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. | Q47349491 | ||
| CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. | Q53551795 | ||
| HIV: Shock and kill. | Q55056512 | ||
| Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIV‐1 Vaccine Candidates | Q58758928 | ||
| Ex vivo T cell–based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses | Q61365513 | ||
| Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection | Q84409867 | ||
| Modeling the within-host dynamics of HIV infection | Q21245370 | ||
| Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection | Q24645815 | ||
| Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 | ||
| HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors | Q24676982 | ||
| Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions | Q26777442 | ||
| HIV therapeutic vaccines: moving towards a functional cure | Q27002180 | ||
| Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes | Q27324527 | ||
| Depletion of latent HIV-1 infection in vivo: a proof-of-concept study | Q28111910 | ||
| Tetrameric complexes of HLA-E, HLA-F, and HLA-G | Q28221089 | ||
| Adoptive immunotherapy for cancer: harnessing the T cell response | Q28262548 | ||
| Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection | Q28481938 | ||
| An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression | Q28546918 | ||
| Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 | Q28655602 | ||
| Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency | Q28728736 | ||
| Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption | Q28742727 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 | ||
| HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 | ||
| IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. | Q33210552 | ||
| Revisiting estimates of CTL killing rates in vivo | Q33309946 | ||
| Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection | Q33554940 | ||
| Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques | Q33554963 | ||
| Timely HAART initiation may pave the way for a better viral control | Q33833189 | ||
| Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy | Q33843388 | ||
| Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors | Q33869222 | ||
| Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion | Q33987485 | ||
| Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys | Q34020988 | ||
| Short-course antiretroviral therapy in primary HIV infection | Q34037516 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection | Q34315612 | ||
| HIV-1 DNA predicts disease progression and post-treatment virological control | Q34350410 | ||
| Immune interventions in HIV infection | Q34351326 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| Absence of detectable HIV-1 viremia after treatment cessation in an infant | Q34379777 | ||
| Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases | Q34539993 | ||
| Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction | Q34570127 | ||
| Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies | Q34593086 | ||
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study | Q34629153 | ||
| Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. | Q34891171 | ||
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
| HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo | Q35029956 | ||
| Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy | Q35036284 | ||
| B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers | Q35058635 | ||
| Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes | Q35110576 | ||
| Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption | Q35190018 | ||
| Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. | Q35214233 | ||
| A hardwired HIV latency program | Q35400385 | ||
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
| Post-treatment control of HIV infection | Q35567047 | ||
| Viremic relapse after HIV-1 remission in a perinatally infected child | Q35633017 | ||
| HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission | Q35680431 | ||
| Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation | Q35685446 | ||
| Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo | Q35718251 | ||
| The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo | Q35778783 | ||
| An evolutionary role for HIV latency in enhancing viral transmission | Q35807225 | ||
| Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir | Q35812943 | ||
| Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point | Q36074846 | ||
| Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication | Q36086631 | ||
| Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
| Immunological biomarkers predict HIV-1 viral rebound after treatment interruption | Q36250043 | ||
| Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. | Q36369035 | ||
| Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy | Q36379282 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection | Q36513955 | ||
| Molecular mechanisms of HIV latency | Q36515063 | ||
| Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
| Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. | Q36602033 | ||
| Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E. | Q36624194 | ||
| Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation | Q36796554 | ||
| Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection | Q36979967 | ||
| CD8+ T cell efficacy in vaccination and disease | Q37184070 | ||
| Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms | Q37278451 | ||
| Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection | Q37366149 | ||
| The challenge of finding a cure for HIV infection | Q37407598 | ||
| Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. | Q37410726 | ||
| Vaccine-induced CD8+ T cells control AIDS virus replication | Q37442789 | ||
| Phenotype and function of protective T cell immune responses in HIV. | Q37447721 | ||
| Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells | Q37638811 | ||
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. | Q37695001 | ||
| The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors | Q37773161 | ||
| Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection | Q37852942 | ||
| HIV and inflammation: mechanisms and consequences | Q38005046 | ||
| Toward a cure for HIV--Seeking effective therapeutic vaccine strategies | Q38626469 | ||
| Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection | Q38860933 | ||
| Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription | Q39173861 | ||
| Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. | Q39549058 | ||
| Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy | Q39595379 | ||
| Efficient inhibition of SIV replication in rhesus CD4+ T-cell clones by autologous immortalized SIV-specific CD8+ T-cell clones | Q40037426 | ||
| A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells | Q40336664 | ||
| HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report | Q40834710 | ||
| Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir | Q40845612 | ||
| Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth | Q41448532 | ||
| Modeling the timing of antilatency drug administration during HIV treatment | Q41727164 | ||
| Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection | Q41857492 | ||
| Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells | Q41915015 | ||
| Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). | Q42691966 | ||
| Cell-based flow cytometry assay to measure cytotoxic activity | Q42749261 | ||
| Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression | Q43655245 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 409-416 | |
| P577 | publication date | 2016-04-06 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | Kill: boosting HIV-specific immune responses | |
| P478 | volume | 11 |
| Q38433251 | Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection. |
| Q98772201 | Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency |
| Q40080802 | HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal |
| Q54217623 | Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection. |
| Q92657640 | Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy |
| Q64071164 | Priming of HIV-1-specific CD8 T cells with strong functional properties from naïve T cells |
| Q45874441 | Wake me up before you go: A strategy to reduce the latent HIV reservoir |
Search more.